Pharmaceutical Technology on MSN6d
EMA to review GSK’s Nucala for COPD treatment expansion
The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on ...
European regulators to review GSK's asthma drug Nucala to treat COPD
The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...
Nature1mon
Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies?
Other caveats include the small number of patients with each PID, which may prevent a comprehensive description of the infectious phenotype. Moreover, antibodies may be administered at an age at ...